183 related articles for article (PubMed ID: 37345138)
1. PSMA-PET/CT-Based Stereotactic Body Radiotherapy (SBRT) in the Treatment of Uncomplicated Non-Spinal Bone Oligometastases from Prostate Cancer.
Pastorello E; Nicosia L; Cuccia F; Olivari L; Fiorini M; Giaj Levra N; Mazzola R; Ricchetti F; Rigo M; Ravelli P; D'Alessandro S; Salgarello M; Ruggieri R; Alongi F
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345138
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience.
Cuccia F; Tamburo M; Piras A; Mortellaro G; Iudica A; Daidone A; Federico M; Zagardo V; Ferini G; Marletta F; Spatola C; Fazio I; Filosto S; Pergolizzi S; Ferrera G
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629732
[No Abstract] [Full Text] [Related]
4. Metastasis-directed Therapy (SBRT) Guided by PET-CT
Mazzola R; Francolini G; Triggiani L; Napoli G; Cuccia F; Nicosia L; Livi L; Magrini SM; Salgarello M; Alongi F
Clin Genitourin Cancer; 2021 Jun; 19(3):230-236. PubMed ID: 32863189
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
6. PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study.
Mazzola R; Cuccia F; Pastorello E; Salgarello M; Francolini G; Livi L; Triggiani L; Magrini SM; Ingrosso G; Aristei C; Franzese C; Scorsetti M; Alongi F
Clin Exp Metastasis; 2022 Jun; 39(3):443-448. PubMed ID: 35266063
[TBL] [Abstract][Full Text] [Related]
7. Progression-free survival in patients with
Werensteijn-Honingh AM; Wevers AFJ; Peters M; Kroon PS; Intven M; Eppinga WSC; Jürgenliemk-Schulz IM
Acta Oncol; 2021 Oct; 60(10):1342-1351. PubMed ID: 34323648
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Body Radiotherapy for Spine Oligometastases: A Multicentre Retrospective Study From the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Cuccia F; Pastorello E; Franzese C; Belgioia L; Bignardi M; Federico M; Figlia V; Giaj Levra N; Badellino S; Borghetti P; Marvaso G; Montesi G; Pontoriero A; Fazio I; Ferrera G; Alongi F; Scorsetti M
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):794-800. PubMed ID: 37714793
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes of metastasis-directed treatment using
Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
[TBL] [Abstract][Full Text] [Related]
10.
Marzec J; Becker J; Paulsen F; Wegener D; Olthof SC; Pfannenberg C; Schwenck J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
Acta Oncol; 2020 Feb; 59(2):149-156. PubMed ID: 31559880
[No Abstract] [Full Text] [Related]
11. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
Kalinauskaite G; Senger C; Kluge A; Furth C; Kufeld M; Tinhofer I; Budach V; Beck M; Hochreiter A; Grün A; Stromberger C
PLoS One; 2020; 15(10):e0240892. PubMed ID: 33085712
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial.
Siva S; Bressel M; Murphy DG; Shaw M; Chander S; Violet J; Tai KH; Udovicich C; Lim A; Selbie L; Hofman MS; Kron T; Moon D; Goad J; Lawrentschuk N; Foroudi F
Eur Urol; 2018 Oct; 74(4):455-462. PubMed ID: 30227924
[TBL] [Abstract][Full Text] [Related]
14. 30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease.
Osti MF; Agolli L; Valeriani M; Reverberi C; Bracci S; Marinelli L; De Sanctis V; Cortesi E; Martelli M; De Dominicis C; Minniti G; Nicosia L
Lung Cancer; 2018 Aug; 122():165-170. PubMed ID: 30032826
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
16. 1.5 T MR-Guided Daily Adapted SBRT on Lymph Node Oligometastases from Prostate Cancer.
Nicosia L; Trapani G; Rigo M; Giaj-Levra N; Mazzola R; Pastorello E; Ricchetti F; Cuccia F; Figlia V; Fiorini M; Alongi F
J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431135
[No Abstract] [Full Text] [Related]
17. Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT).
Habl G; Straube C; Schiller K; Duma MN; Oechsner M; Kessel KA; Eiber M; Schwaiger M; Kübler H; Gschwend JE; Combs SE
BMC Cancer; 2017 May; 17(1):361. PubMed ID: 28532400
[TBL] [Abstract][Full Text] [Related]
18. Metabolic response after 68Ga-PSMA-PET/CT-directed IGRT/SBRT for oligometastases prostate cancer.
Gawish A; Abdullayev N; El-Arayedh S; Röllich B; Ochel HJ; Brunner TB
Clin Transl Oncol; 2023 Apr; 25(4):987-994. PubMed ID: 36369631
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study.
Mazzola R; Fersino S; Ferrera G; Targher G; Figlia V; Triggiani L; Pasinetti N; Lo Casto A; Ruggieri R; Magrini SM; Alongi F
Med Oncol; 2018 Aug; 35(9):121. PubMed ID: 30076479
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.
Rogé M; Pointreau Y; Sargos P; Meyer E; Schick U; Hasbini A; Rio E; Bera G; Ruffier A; Quivrin M; Chasseray M; Latorzeff I; Martin E; Guimas V; Pommier P; Leroy T; Ronchin P; Lepinoy A; Grand A; Cartier L; Didas O; Denis F; Libois V; Blanc-Lapierre A; Supiot S
Clin Transl Radiat Oncol; 2023 May; 40():100613. PubMed ID: 36968576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]